|
Biotech Advances In The Spotlight At Biotrinity 2008 Oxford
April 15-16, Quadrangle at Kassam, Oxford, UK
Download the preliminary programme (PDF)
Oxford, UK February 11 2008. BioTrinity, OBN’s leading partnering and networking event, will this year focus on the current trends and latest issues affecting the UK’s fast growing biotech industry. This year’s agenda will feature a number of keynote speakers, currently achieving considerable milestones in today’s volatile economic climate. Dr Christian Rohlff, CEO, Oxford Genome Sciences (OGeS) is the most recent speaker to confirm his position on the programme.
In the past two years OGeS has positioned itself as an emerging force in the field of novel antibody therapeutics for the treatment of cancer. In December, as part of this strategy, the company announced a partnership with Amgen, one of the world’s largest biotechnology companies, which will provide OGeS with access to the US companys XenoMouse technology for antibody generation. Dr. Rohlff will be speaking at the ‘Most Promising Emerging Companies Showcase.’
Oxford Genome Sciences is one of twenty five of the most promising emerging drug discovery companies in the South East of England chosen for BioTrinity by an expert panel put together by the Oxfordshire Bioscience Network (OBN).
BioTrinity 2008 speakers include:
- Charlie Alexander, Director of Business Development, Shire
- Shaun Grady, VP Deal Management, AstraZeneca
- Graziano Seghezzi, Partner, Sofinnova Partners
- Zina Affas, Principal (Life Sciences), Atlas Venture
- David Mott, Investment Director, Oxford Capital Partners
- Eliot Forster, CEO, Solace Pharma
- Charles Potter, CEO, Glide Pharma
- Thomas Schall, CEO, Chemocentryx
- Robert Miller, CEO, Phynova
- Mark Ashton, EVP Business Development, Evotec
- Steven Lee, CEO, Summit plc
- Anker Lundemose, President, (OSI) Prosidion
Among our recent BioTrinity delegates see which companies have already signed up.
Dr. Jon Rees, Director of OBN commented: "We are very pleased to be host to so many prestigious speakers at BioTrinity 2008, specifically Dr. Rohlff. Oxford Genomes Sciences’ recent announcement of a deal with Amgen is highly significant in the development of novel antibody therapies and for the future of drug discovery and development. OGeS’s involvement in BioTrinity 2008 will enable delegates and contributors to receive the most up-to-date account of developments in this area and will provide them with the opportunity to participate in partnering discussions with key industry players."
Dr Rohlff Commented: "I am very pleased to be speaking at BioTrinity and to have the opportunity to set out how OGeS has transformed itself from a biomarker development company to an emerging force in the field of novel antibody therapeutics for the treatment of cancer. To achieve this goal OGeS has had a very pro-active business development strategy and we now have strategic partnerships with leading antibody companies including Medarex, Amgen and BioSite. These partnerships have allowed us to create a pipeline of novel antibody therapeutics based on our unique OGAP® (Oxford Genome Anatomy Project) platform, the world’s largest proprietary human protein database. I look forward to discussing these collaborations and sharing our vision for the future of the industry with the attendees at BioTrinity."
BioTrinity is taking place on the 15th and 16th April Oxford, UK and provides the opportunity to view the latest presentations from top tier companies drawn from the UK’s most successful biotech super cluster in Oxford and the South East of England, and to partner with them.
More conference details are available online at: www.biotrinity.com
...........................................................................................
BioTrinity 2008 testimonials:
Testimonial from a Venture Capitalst firm (read more testimonials):
"...the conference was a great success. There was a high calibre of participants and the event has raised the profile the Oxford and Thames Valley biotech cluster. This will create a rising tide for us all."
David Mott, Investment Director, Oxford Capital Partners
...........................................................................................
BioTrinity 2008 features:
-
Two full days of partnering in private rooms as standard for under £500!
-
A multi-track programme incorporating Key-notes and Key-deals by prominent speakers on the growth and development of the sector; Panel discussions on Venture Capital; Alliances and Licensing; The Most Promising Emerging Companies showcase; Clinical Stage Developments showcase; Technology showcase of licensing opportunities and spin outs; Sponsor led and independent workshops on deal making, funding, business planning and alliance; the Bio-IT Showcase
- Two networking events (including the launch of the OBN 2008 BioCluster Report) and ample opportunities for informal networking via breakfasts, lunches and refreshment breaks.
A high visibility exhibition amidst partnering terminals, catering and networking areas. In par with BioTrinity 2007, spaces are selling fast.
............................................................................................
Contact details:
Aruna Dudhia – Events Manager OBN
Suite L, Park House
11 Milton Park, Abingdon
Oxfordshire OX14 4RA
Tel. +44 (0) 1865 594641
Fax. +44 (0) 1235 835843
aruna.dudhia@oxfordshirebioscience.net
Register online now at www.biotrinity.com
............................................................................................
BioTrinity sponsors
  
 
   
............................................................................................
BioTrinity partners
 
 
............................................................................................
BioTrinity is organised by OBN
|
BioTrinity 2008
|
)